BIOCLONAL
Contact information
- Biodrugs
- Biomarkers
- Drug discovery
- Inflammatory diseases
- Immunology
- Ophtalmology and optometry
- Oncology
- Central nervous system
- CRO / CMO / SMO
BioClonal S.L. is a biotechnology company that seeks to be a benchmark in the field of immunization. They develop monoclonal antibodies for use in human therapy, which devises an in vivo technology platform of its creation: RedMabs. They wnat to contribute all our knowledge to the ecosystem so that together can generate btter drugs and improve people´s quality of life.
Our activity fits in research and experimental development in biotechnology. Specifically, the company focuses on the discovery phase, from the conception of the idea to the sequence of the base monoclonal or the purified antibody. Today, the objective is to develop a platform for the discovery of antibodies for use in human therapy, through their exclusive technological platform, and to be the partner of other platforms at a international level.
Monoclonal antibodies for use in human therapy.
Drug Disovery: Our business model is bases on long-term collaboration so that use of our technology enables the generation of antibodies.
Biotech Sanitaria
| Product / Service | Type | Therapeutic area | Aplication | Development phase |
|---|---|---|---|---|
| Amyloid-Beta–derived biomarker antibody program | Biomarkers, Diagnostic | Sistema nervioso central | Intended for use as in vitro diagnostic and research reagents, and as investigational therapeutic antibodies. Applications include integration into ultrasensitive immunoassays for biomarker detection and quantification, clinical and translational research, assay development and validation, and as potential therapeutic agents to modulate circulating levels of the derived amyloid-beta peptide in patients. This program represents the next step in expanding our Alzheimer’s disease peptide-targeted antibody portfolio. | R&D |
| Amyloid-Beta biomarker antibody program (Aβ 1–16) | Diagnostic | Sistema nervioso central | Intended for use as in vitro diagnostic and research reagents, including integration into ultrasensitive immunoassays for detection and quantification of Aβ 1–16. Applications include clinical and translational research, biomarker studies, assay development and validation, and use as analytical or reference reagents for monitoring Alzheimer’s disease–related peptides in biological samples. | R&D |
| Peptide-based diagnostic antibodies for Diabetes | Diagnostic | Trastornos metabólicos / Endocrinología | Intended for use as in vitro diagnostic reagents in diabetes testing, with application in ultrasensitive immunoassays for biomarker quantification. Use cases include integration into diagnostic platforms, assay development and validation, clinical research, and use as analytical or reference reagents for monitoring insulin, proinsulin and C-peptide levels in biological samples. | R&D |